The mucosal atomization devices market is projected to record a CAGR of nearly 7.25% over the forecast period.
The COVID-19 pandemic is an unprecedented health concern and is adversely affecting communities, industries, businesses, and lives around the world. Many companies have already received approval for their vaccines against the Sars-CoV-2 virus and still focusing their research and development on the development of therapeutics against the COVID-19. As per the Cooper University of Healthcare, COVID-19 and sinusitis have similar symptoms, such as nasal congestion, fever, and cough. The COVID-19, being a respiratory tract infection, affects the upper respiratory tract including the sinuses, nose, and throat or lower respiratory tract including the windpipe and lungs. However, there is no clinical evidence that COVID-19 is causing sinus infection. As per a survey conducted by the International Archives of Allergy and Immunology in January 2021, only 13% of physicians continued skin prick testing with commercial inhalant extracts while 31% of physicians performed skin pricking test in rare case. However, all of the respondents were observed continuing their asthma and allergic rhinitis medication including inhaled corticosteroids, long-acting β2-agonists, Montelukast sodium, antihistamines, and nasal steroids. Over 92% of the physicians reported prescribing inhaled medications to COVID-19 patients for instances of emergency management.
The major factor attributing to the growth of the market is the increase in the adoption of mucosal atomization devices due to the non-invasive nature of these devices. Furthermore, these devices offer quicker recovery and are less painful options. Mucosal atomization devices help in faster delivery of medication in the bloodstream, thus reducing the time for the therapeutics to act on the concerned medical issue. As these drugs directly enter the bloodstream, they avoid first-pass metabolism and give quicker results.
Moreover, the increasing prevalence of allergic rhinitis and sinus across the world is another major factor propelling market growth. However, the side effects of the devices due to overdose of drugs are the drawback of the market growth.
Key Market Trends
Gas Propelled Segment is the Fast Growing Segment Over the Forecast Period
Gas powered or propelled drug delivery system was one of the first developed. It uses a gas or air cartridge attached to the gun either directly or indirectly through a tubing system to deliver power to the injector piston. When the trigger is activated, it releases the piston and creates a jet stream of medicant through Nasal, buccal and trachea. Gas-propelled delivery offers the benefit of being extremely flexible. Owing to the variety of liquefied gases available, it’s possible to provide a complete spectrum of pressure ranges within a single container format. This allows a single device system to manage a variety of delivery options, including different viscosities (up to 300 cP and much higher with a new variation on the technology), injection volumes, and primary containers.
Several key players in the market are focusing on developing novel gas propelled devices for the easy and safe administration of drugs. Bespak is one such company that offers a broad portfolio of gas-propelled drug delivery devices. The company’s Unidose Xtra nasal spray device is one such device and is a customizable spray device for the drug delivery of various requirements of patients. Unidose (UDS) systems are ready-to-use, one-step nasal drug delivery devices that convert liquid formulations to release the medicament as spray using gas or air powered technology. Impel NeuroPharma is developing Precision Olfactory Delivery (POD) technology, a proprietary drug delivery technology system, that uses gas propelling technology to target the vascular rich upper nasal space. In January 2021, United States Food and Drug Administartion accepted the company’s 5O5(b)(2) New Drug Application (NDA) for INP104 for the acute treatment of migraine headaches with or without aura in adults. INP104 is dihydroergotamine mesylate (DHE) delivered directly into the vascular-rich upper nasal space using Impel’s proprietary Precision Olfactory Delivery (POD) technology.
Thus, owing to the aforementioned factors, the application of gas propelled mucosal atomization devices are expected to grow significantly during the forecast period.
North America Dominates the Market and is Expected to do the Same over the Forecast Period
North America is expected to dominate the overall market throughout the forecast period. The market growth is due to the factors, such as the presence of key players, high prevalence of allergic rhinitis and sinus in the region, and established healthcare infrastructure. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. In this region, the United States has the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market.
Allergic rhinitis affects approximately 20 percent of people of all ages. The risk of developing allergic rhinitis is much higher in people with asthma or eczema and in people who have a family history of asthma or allergic rhinitis in the country according to the article "Patient education: Allergic rhinitis (Beyond the Basics)" published by Richard D deShazo in June 2021. As the Mucosal atomization devices are primarily used to deliver drugs through nasal mucosa for treating chronic diseases such as allergic rhinitis and sinusitis, the increasing burden of these diseases in the country lead to the growing demand of the devices. The MAD Nasal Intranasal Mucosal Atomization Device from Teleflex is the safe and painless way to deliver medications. This device atomizes drugs into a fine mist of particles 30-100 microns in size. The presence of many top players like Becton, Dickinson and Company, DeVilbiss Healthcare LLC, in the country is also a major reason behind its huge share in the market. Thus, due to above-mentioned factors, the studied market is expecetd to grow over teh forecast period.
The Mucosal Atomization Devices market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Teleflex Incorporated, DeVilbiss Healthcare LLC, Becton, Dickinson and Company, Kurve Technology, Inc, Cook Medical, Medica Holdings.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Increasing Adoption of Mucosal Atomization Devices
4.2.2 Increasing Prevalence of Allergic Rhinitis and Sinus
4.3 Market Restraints
4.3.1 Side Effects Due to Overdose
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Gas Propelled
5.2 By End User
5.2.3 Other End Users
5.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.3.4 Rest of the World
6.1.1 Teleflex Incorporated
6.1.2 DeVilbiss Healthcare LLC
6.1.3 Becton, Dickinson and Company
6.1.4 Kurve Technology Inc.
6.1.5 Cook Medical
6.1.6 Medica Holdings
6.1.7 Integra LifeSciences
6.1.8 BVM Meditech Private Limited
A selection of companies mentioned in this report includes:
- Teleflex Incorporated
- DeVilbiss Healthcare LLC
- Becton, Dickinson and Company
- Kurve Technology Inc.
- Cook Medical
- Medica Holdings
- Integra LifeSciences
- BVM Meditech Private Limited